Cargando…
Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
SIMPLE SUMMARY: Alpelisib is a drug used to treat breast cancer that has certain characteristics (hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2–), PIK3CA-mutated) and that has or has not spread to other organs. It is used after the cancer has progressed despite be...
Autores principales: | Tankova, Tsvetalina, Senkus, Elżbieta, Beloyartseva, Maria, Borštnar, Simona, Catrinoiu, Doina, Frolova, Mona, Hegmane, Alinta, Janež, Andrej, Krnić, Mladen, Lengyel, Zoltan, Marcou, Yiola, Mazilu, Laura, Mrinakova, Bela, Percik, Ruth, Petrakova, Katarina, Rubovszky, Gábor, Tokar, Margarita, Vrdoljak, Eduard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997133/ https://www.ncbi.nlm.nih.gov/pubmed/35406370 http://dx.doi.org/10.3390/cancers14071598 |
Ejemplares similares
-
Treating Alpelisib-Induced Hyperinsulinemia in Patients with Advanced Breast Cancer – A Real-Life Experience
por: Percik, Ruth, et al.
Publicado: (2023) -
The Role of Vaspin in the Development of Metabolic and Glucose Tolerance Disorders and Atherosclerosis
por: Dimova, Rumyana, et al.
Publicado: (2015) -
Diabetic Ketoacidosis With Alpelisib
por: Jeun, Rebecca, et al.
Publicado: (2021) -
Alpelisib for breast cancer
Publicado: (2022) -
Alpelisib-Induced Diabetic Ketoacidosis
por: Espinosa, Luis Borges, et al.
Publicado: (2021)